T细胞失调提示B细胞淋巴瘤放疗-免疫治疗反应:一项1期试验结果
这项1期研究在34例复发/难治性弥漫大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)成人患者中,评估递增放疗剂量与照射体积联合度伐利尤单抗的安全性及免疫细胞亚群对结局的作用。FL的客观缓解率为60%(3/5),DLBCL为14%(4/27)。外周血和肿瘤T细胞特征(包括CD8 PET测定的瘤内CD8 T细胞)与缓解相关(P < .05)。
要点
- FL的推荐2期放疗剂量为10 Gy/5次,DLBCL为30 Gy/10次,照射3个部位。
- FL客观缓解率60%(3/5),完全缓解40%(2/5);DLBCL客观缓解率14%(4/27),完全缓解7%(2/27)。
- 最常见3-4级毒性为贫血(9%)、中性粒细胞减少(11%)和肝功能障碍(5%)。
核心结论
- 30 Gy/10次放疗照射3个部位联合度伐利尤单抗是安全的,在FL中提供有希望的缓解。
- 瘤内和外周血CD8 T细胞失调与治疗缓解相关。
研究设计与样本
- 1期研究纳入34例复发/难治性DLBCL和复发/难治性FL成人患者。
- 患者接受外照射放疗(2.5-30 Gy,5或10次,最多3个靶部位)联合度伐利尤单抗,自放疗第2天开始直至进展。
- 研究纳入89Zr-度伐利尤单抗和CD8 T细胞minibody-89Zr-Df-crefmirlimab的新型PET生物分布研究。
- 试验注册号为NCT03610061。
主要发现
- FL客观缓解率为60%(3/5),完全缓解率为40%(2/5);DLBCL客观缓解率为14%(4/27),完全缓解率为7%(2/27)。
- 外周血和肿瘤T细胞特征(包括CD8 PET测定的瘤内CD8 T细胞)与缓解相关(P < .05)。
- 最常见3-4级毒性包括贫血(9%)、中性粒细胞减少(11%)和肝功能障碍(5%)。
关键数值与推荐
- FL的放疗推荐2期剂量为10 Gy/5次,DLBCL为30 Gy/10次,照射3个部位。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL/FL; however, evidence suggests synergy with radiotherapy (RT), but no clear biomarkers. This phase 1 study examined the safety of escalating RT dose and treated volumes with durvalumab (PD-L1 inhibitor) in 34 adults with relapsed/refractory DLBCL and relapsed/refractory FL, and the role of immune-cell subsets on outcomes. Patients received external-beam RT (2.5-30 Gray [Gy], 5 or 10 fractions up to 3 target sites) plus durvalumab from RT day 2, until progression. Novel positron emission tomography (PET) biodistribution studies of 89Zr-durvalumab and CD8 T-cell minibody-89Zr-Df-crefmirlimab were incorporated. The RT recommended phase 2 dose was 10 Gy/5 fractions and 30 Gy/10 fractions to 3 sites for FL and DLBCL, respectively. The most common grade 3 to 4 toxicities included anemia (9%), neutropenia (11%), and liver dysfunction (5%). Overall response was 60% in FL (3/5; complete response, 40% [2/5]), and 14% in DLBCL (4/27; complete response, 7% [2/27]). Distinct peripheral blood and tumor T-cell features, including CD8 PET-determined intratumoral CD8 T-cells, correlated with response (P < .05). RT-durvalumab with 30 Gy/10 fractions of RT to 3 disease sites is safe, and offers promising responses in FL. Intratumoral and peripheral blood CD8 T-cell dysregulation correlate with treatment response. This trial was registered at www.clinicaltrials.gov as #NCT03610061.
引用
- Hawkes EA, Palmer JB, Khor R, et al. T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. Blood Adv. 2025. PMID: 40540795. doi:10.1182/bloodadvances.2025016505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。